Loebel, Madlen, Grabowski, Patricia, Heidecke, Harald et al. · Brain, behavior, and immunity · 2016 · DOI
Researchers tested whether ME/CFS patients have unusually high levels of antibodies (immune proteins) that attack nerve signaling receptors in the body. They found that about 30% of ME/CFS patients had elevated antibodies against certain receptors involved in adrenaline and acetylcholine signaling—chemicals that control heart rate, breathing, and other automatic body functions. Importantly, patients who received rituximab (a treatment that depletes B cells) and improved showed decreases in these antibody levels, suggesting a possible link between these antibodies and disease activity.
This study provides evidence for an autoimmune mechanism in ME/CFS by identifying specific autoantibodies that correlate with immune activation and autonomic symptoms. The finding that antibody levels decline with effective B-cell depletion therapy suggests a potential biological marker for predicting treatment response, which could guide personalized clinical management and validate immunotherapeutic approaches in ME/CFS.
This study does not prove that these autoantibodies directly cause ME/CFS symptoms or dysfunction; it demonstrates correlation and association. The study is not a functional assay—it does not show that these antibodies functionally impair receptor signaling in vivo. The cross-sectional Berlin cohort design cannot establish causation, and the small rituximab sample (n=25) limits generalizability of treatment-response findings.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →